Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 13/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643806 | 0.85 | SIRT1 (0.42) | SIRT1CYP19A1CHRM2ADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL3734801 | 0.84 | SIRT1 (0.41) | SIRT1CYP19A1CHRM2ADRA2ACHRM1 | |
| SCHEMBL961871 | 0.82 | F2RL3 (0.41) | SIRT1CYP19A1CHRM2ADRA2ACHRM1 | |
| SCHEMBL3684024 | 0.79 | CYP19A1 (0.37) | SIRT1CYP19A1CHRM2ADRA2ACHRM1 | |
| SCHEMBL11987212 | 0.78 | SIRT1 (0.42) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL222169 | 0.78 | SIRT1 (0.52) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL13470784 | 0.76 | SIRT1 (0.41) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL4610482 | 0.76 | SIRT1 (0.65) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL221866 | 0.76 | SIRT1 (0.50) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL220546 | 0.75 | SIRT1 (0.38) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167510-B1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2167510-B1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8247565-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247565-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247565-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-7829556-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829556-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829556-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2167510-A1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008156866-A1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156866-A1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012080-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885CYP19A1 944/4885CHRM2 4269/4885 |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885CYP19A1 1201/4885CHRM2 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.